CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation

Area of Science:

• Immunology
• Neuroendocrinology
• Dermatology

Background:

• Langerhans cells (LCs) are key immune cells in the skin.
• Neuropeptides (NP) such as calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), and vasoactive intestinal peptide (VIP) are known to modulate immune responses.
• The precise mechanisms by which these NPs influence LC function are not fully understood.

Purpose of the Study:

• To investigate the hypothesis that CGRP, PACAP, and VIP inhibit LC function by modulating NF-kappaB activation.
• To elucidate the signaling pathways involved in NP-mediated inhibition of LC function.

Main Methods:

• Utilized a LC-like cell line (XS52) and primary human epidermal LCs.
• Stimulated cells with lipopolysaccharide (LPS) and assessed NF-kappaB activation.
• Measured phosphorylation of IkappaB kinase beta (P-IKKbeta) and degradation of IkappaB alpha.
• Quantified tumor necrosis factor-alpha (TNFalpha) production.
• Assessed LC antigen presentation capacity in vitro using a T-cell clone.

Main Results:

• LPS-induced NF-kappaB activation in LCs was inhibited by CGRP, PACAP, and VIP.
• These neuropeptides suppressed P-IKKbeta, prevented IkappaB alpha degradation, and inhibited NF-kappaB activation.
• CGRP, PACAP, and VIP reduced LPS-induced TNFalpha secretion from LCs.
• Inhibition of IKK with Bay 11-7085 mimicked NP effects, reducing TNFalpha production and LC antigen presentation.

Conclusions:

• CGRP, PACAP, and VIP modulate LC function, at least partly, by inhibiting IKKbeta activation, thereby preventing IkappaB alpha degradation and NF-kappaB activation.
• These findings suggest that targeting the IKKbeta/NF-kappaB pathway by these neuropeptides could be a therapeutic strategy for modulating skin immunity.